CCR News: Clinical Trials

Lipogenesis in Prostate Cancer

Combination therapy for biochemically recurrent prostate cancer tested in new trial

May 31, 2018

Prostate-specific antigen (PSA) is an enzyme released by the prostate gland and is found in abnormally high concentrations in the blood of men with prostate cancer. “Biochemical recurrence” is when PSA levels continue to rise after initial treatment for prostate cancer, such as surgery or radiation. Marijo Bilusic, M.D., of the Genitourinary Malignancies Branch is leading the Center for Cancer Research’s effort in a study to treat men with biochemically recurrent prostate cancer with a combination drug therapy. Read more...

Mesothelioma Spheroid

Clinical trial tests drug combination in mesothelioma of the lung or abdomen

May 29, 2018

Mesothelioma is an aggressive form of cancer caused by asbestos with no known cure and a very poor prognosis. Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch is leading a study to determine a safe dose of a combination drug therapy in patients with advanced mesothelioma.  Read more...

Pancreatic cancer

Clinical trial investigates experimental drug for advanced pancreatic cancer

May 23, 2018

The pancreas, a large gland that sits behind the stomach, produces enzymes that aid digestion and hormones that regulate blood sugar. Pancreatic cancer develops when cells that make up the ducts in the pancreas start to grow out of control. Udo Rudloff, M.D., is leading a clinical trial of a combination immunotherapy regimen to optimally help the immune system attack the tumor. Read more...

T cell

New trial engineers immune cells to treat solid tumors

May 18, 2018

No existing systemic treatments can currently eradicate the great majority of metastatic solid cancers. To meet that need, Steve Rosenberg, M.D., Ph.D., is testing a new immunotherapy that targets each tumor’s unique genetic mutations in a clinical trial. Read more...

Epstein-Barr virus

New clinical trial uses targeted cancer drug for lymphatic system disease

May 16, 2018

Nivolumab is a targeted cancer drug that blocks the action of a protein called PD-1 and activates T cells to attack cancer cells without damaging normal cells. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading a study to determine if nivolumab is effective in treating patients with certain diseases of the lymphatic system. Read more...

HPV

Clinical trial tests first-in-class bifunctional immunotherapy drug in HPV-associated cancers

May 14, 2018

HPV-associated cancers that spread or do not respond to treatment are often incurable. Julius Strauss, M.D., of the Laboratory of Tumor Immunology and Biology is testing a first-in-class bifunctional immunotherapy to see if it can control the growth of HPV-associated tumors by restoring and improving the immune system’s ability to kill cancer cells. Read more...

Dividing Breast Cancer Cell

New trial evaluates investigational drug for endometrial and breast cancers

Apr 24, 2018

A new clinical trial is testing ONC201, an investigational drug that in laboratory studies has been shown to kill breast and endometrial cancer cells most likely by destroying mitochondria within the tumor cells. Mitochondria are the “powerhouse” of the cell, and blocking its activity may kill tumor cells and shrink tumors in human patients. Read more...

Tracie Miller and Steve Lipshultz

A physician faces her own ovarian cancer

Apr 23, 2018

Drs. Tracie Miller and Steve Lipshultz have spent their careers caring for pediatric patients and conducting research at well-known medical institutions across the country. In some ways, those years of providing patient care and conducting medical research prepared the couple for Tracie’s ovarian cancer diagnosis, and in other ways, it didn’t. Read more...

Prostate cancer

Combination immunotherapy clinical trial for prostate cancer patients with rise in PSA

Apr 20, 2018

A new study that is now open is testing combination immunotherapy for men with prostate cancer that are experiencing a rise in PSA after surgery or radiation.  Read more...

leukemia cells

Phase I clinical trial will test multi-targeted immunotherapy in common childhood cancer

Apr 10, 2018

Chimeric antigen receptor (CAR) T-cell immunotherapy targeting the protein CD19 has shown promise in treating acute lymphoblastic leukemia (ALL). CD22-CAR T-cell therapy has yielded similarly encouraging results, but many patients relapse after either therapy. In an upcoming phase I clinical trial, Center for Cancer Research investigators will test a new strategy—treating patients with a CAR T-cell therapy that targets CD19 and CD22 simultaneously. Read more...

Pages